Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Newron Pharmaceuticals SpA ( (CH:NWRN) ) has issued an update.
Newron reported 2025 as a landmark year, driven by progress in its Evenamide program, including regulatory approval and initiation of the pivotal ENIGMA-TRS phase III trials in treatment-resistant schizophrenia across multiple regions. Partner EA Pharma launched a phase III trial in Japan, while Newron secured an additional European composition-of-matter patent for Evenamide extending exclusivity to 2044.
The company strengthened its scientific and market profile through multiple peer-reviewed publications and conference presentations supporting Evenamide’s novel mechanism and broad symptom coverage in schizophrenia. Corporate developments included a new board chairman, planned refresh of independent directors, expanded analyst coverage, and up to EUR 38 million in new equity plus extended EIB debt maturities, collectively bolstering its cash runway to advance phase III trials and prepare for potential marketing and listing initiatives.
The most recent analyst rating on (CH:NWRN) stock is a Hold with a CHF21.50 price target. To see the full list of analyst forecasts on Newron Pharmaceuticals SpA stock, see the CH:NWRN Stock Forecast page.
More about Newron Pharmaceuticals SpA
Newron Pharmaceuticals S.p.A. is a biopharmaceutical company specializing in innovative therapies for central and peripheral nervous system disorders. Its lead asset, Evenamide, targets treatment-resistant schizophrenia and related indications, positioning the company in a high unmet-need segment of the global neuropsychiatry market.
Average Trading Volume: 146,194
Technical Sentiment Signal: Buy
Current Market Cap: CHF311.4M
Learn more about NWRN stock on TipRanks’ Stock Analysis page.